Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SDCBP | O00560 | 3/20 | 0.37 |
| ▸ | SDC2 | P34741 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15756817 | 0.94 | NPSR1 (0.43) | NPSR1SMN1; SMN2SDCBPSDC2ALDH1A1 | |
| SCHEMBL15756824 | 0.94 | NPSR1 (0.43) | NPSR1SMN1; SMN2SDCBPSDC2ALDH1A1 | |
| SCHEMBL29967328 | 0.92 | NPSR1 (0.42) | NPSR1SMN1; SMN2SDCBPSDC2ALDH1A1 | |
| SCHEMBL29612414 | 0.91 | NPSR1 (0.36) | NPSR1SMN1; SMN2SDCBPSDC2ALDH1A1 | |
| SCHEMBL30064543 | 0.89 | CTSB (0.46) | CTSD | |
| SCHEMBL24191292 | 0.89 | MME (0.37) | MMECTSD | |
| SCHEMBL29380611 | 0.89 | NPSR1 (0.47) | NPSR1SMN1; SMN2SDCBPSDC2ALDH1A1 | |
| SCHEMBL38665440 | 0.85 | QRFPR (0.37) | — | |
| SCHEMBL29980033 | 0.84 | LMNA (0.43) | ALDH1A1MMEPOLB | |
| SCHEMBL29387536 | 0.84 | MME (0.43) | MMECTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| US-12043659-B2 | Humanized and de-immunized antibodies | VIVORYON THERAPEUTICS N.V. (DE) | 2024-07-23 | — | — | US | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | NPSR1 2800/4885SMN1; SMN2 3039/4885SDCBP 3177/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | NPSR1 3781/4885SMN1; SMN2 4094/4885SDCBP 4364/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | NPSR1 3358/4885SMN1; SMN2 4669/4885SDCBP 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.